Sandbox:DN
Template:Atrophic vaginitis Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
Medical Therpay
Topical estrogen creams or tablets may be used vaginally. Oral or transdermal estrogen may be used. See Boxed Warning about estrogen therapy below.
Sexual activity is also helpful. A water-soluble vaginal lubricant may be useful.
Boxed Warning
The labeling of estrogen-only products includes a boxed warning that unopposed estrogen (without progestin) therapy increases the risk of endometrial cancer.
Based on a review of data from the WHI, on January 8 2003 the FDA changed the labeling of all estrogen and estrogen with progestin products for use by postmenopausal women to include a new boxed warning about cardiovascular and other risks. The estrogen-alone sub-study of the WHI reported an increased risk of stroke and deep vein thrombosis (DVT) in postmenopausal women 50 years of age or older and an increased risk of dementia in postmenopausal women 65 years of age or older using 0.625 mg of Premarin conjugated equine estrogens (CEE). The estrogen-plus-progestin substudy of the WHI reported an increased risk of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli and DVT in postmenopausal women 50 years of age or older and an increased risk of dementia in postmenopausal women 65 years of age or older using 0.625 mg of CEE with 2.5 mg of the progestin medroxyprogesterone acetate (MPA).[1][2][3]
References
- ↑ FDA (1-8-2003). "FDA Approves New Labels for Estrogen and Estrogen with Progestin Therapies for Postmenopausal Women Following Review of Women's Health Initiative Data". Retrieved 2006-09-20. Check date values in:
|date=(help) - ↑ "IMPORTANT WARNING". MedlinePlus. Retrieved 2006-09-18.
- ↑
Kolata, Gina (1-9-2003). "F.D.A. Orders Warning on All Estrogen Labels". The New York Times. Retrieved 2006-09-18. Check date values in:
|date=(help)